{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:41:15Z","timestamp":1740112875313,"version":"3.37.3"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009086","name":"Medical University Sofia","doi-asserted-by":"publisher","award":["1\/2014","10\/2014","12.12.2014","B02\/17"],"award-info":[{"award-number":["1\/2014","10\/2014","12.12.2014","B02\/17"]}],"id":[{"id":"10.13039\/100009086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003336","name":"Bulgarian National Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005992","name":"Ministry of Education and Science","doi-asserted-by":"publisher","award":["14.07.2014","B02\/2"],"award-info":[{"award-number":["14.07.2014","B02\/2"]}],"id":[{"id":"10.13039\/501100005992","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ijantimicag.2015.08.010","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T21:44:26Z","timestamp":1442871866000},"page":"703-706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5734-0100","authenticated-orcid":false,"given":"Lyudmila","family":"Boyanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivailo","family":"Evstatiev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Gergova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penka","family":"Yaneva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Mitov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.medmal.2009.10.009","article-title":"Quelles nouveaut\u00e9s en antibioth\u00e9rapie? Update on antimicrobial chemotherapy","volume":"40","author":"Cattoir","year":"2010","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0085","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.curtheres.2012.04.002","article-title":"Linezolid effects on bacterial toxin production and host immune response: review of the evidence","volume":"73","author":"Diep","year":"2012","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0090","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/AAC.05702-11","article-title":"Resistance to linezolid caused by modifications at its binding site on the ribosome","volume":"56","author":"Long","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0095","series-title":"Helicobacter pylori","first-page":"201","article-title":"H. pylori resistance to antibiotics","author":"Boyanova","year":"2011"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0100","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/AAC.44.7.1977-1979.2000","article-title":"In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori","volume":"44","author":"Hirschl","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0105","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/46.2.283","article-title":"Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin\/dalfopristin and new quinolones","volume":"46","author":"S\u00e1nchez","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diagmicrobio.2007.11.008","article-title":"Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods","volume":"60","author":"Boyanova","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0115","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1469-0691.2006.01577.x","article-title":"EUCAST technical note on linezolid","volume":"12","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee","year":"2006","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2015.08.010_bib0120","first-page":"ii17","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 4","key":"10.1016\/j.ijantimicag.2015.08.010_bib0125","first-page":"iv7","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/QCO.0000000000000142","article-title":"Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection?","volume":"28","author":"Dryden","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0135","first-page":"363","article-title":"High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy","volume":"21","author":"Saracino","year":"2012","journal-title":"J Gastrointest Liver Dis"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0140","doi-asserted-by":"crossref","first-page":"505","DOI":"10.5114\/aoms.2013.36917","article-title":"Antimicrobial susceptibility of Helicobacter pylori isolates from Lower Silesia, Poland","volume":"10","author":"Biernat","year":"2014","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0145","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/ajg.2014.222","article-title":"Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance","volume":"109","author":"Park","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2015.08.010_bib0150","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/jac\/dkr155","article-title":"Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model","volume":"66","author":"Baines","year":"2011","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915003143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915003143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T15:52:19Z","timestamp":1656863539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857915003143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0924857915003143"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.08.010","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}